8
Oct
2024

Pharmidea

Exhibitor at CPHI Milan 2024 stand 16D55, Finished Dosage Formulations
  • LV
  • 2015
    On CPHI since
  • 2
    Certificates
  • 100 - 249
    Employees
Company types
Contract Service
Manufacturer/Innovator
Primary activities
Contract Manufacturer
Pharmaceutical Company (generic finished products)
Contact info
Event information
CPHI Milan 2024
  • 08 Oct 2024 - 10 Oct 2024
  • Fiera Milano, Italy
  • Visit us at stand 16D55, Finished Dosage Formulations

Products Featured at CPHI Milan 2024

  • Levosimendan

    Product Levosimendan

    Levosimendan indicated for short-term treatment of acutely decompensated severe chronic heart failure. Form & strength: 2.5mg/ml concentrate for solution for infusion 

  • Carbetocin

    Product Carbetocin

    Carbetocin indicated for the prevention of uterine atony following delivery of the infant by caesarean section under epidural or spinal anaesthesiaForm & strength: 100 mcg/ ml solution for injection
  • Caspofungin

    Product Caspofungin

    Caspofungin  powder for concentrate for solution for infusion
    50mg/vial
    70mg/vial
    Caspofungin is a new class of echinocandin antifungal agent with broad spectrum of activity used to treat a variety of fungal infections.

  • Atosiban

    Product Atosiban

    Atosiban indicated to delay imminent pre-term birth in pregnant adult women.Form & strength: 6.75 mg/ 0.9ml solution for injection and 37.5mg/ 5 ml concentrate for solution for infusion
  • Dexmedetomidine

    Product Dexmedetomidine

    Dexmedetomidine is indicated:1. for sedation of adult Intensive Care Unit patients requiring a sedation level not deeper than arousal in response to verbal stimulation
    2. for sedation of non-intubated adult patients prior to and/or during diagnostic or surgical procedures requiring sedation, i.e. proc...